Our Products

CBT 124

Indications: Multiple Cancers

Product: Monoclonal Antibody Angiogenesis inhibitor which starves the cancer cells. Targeted therapy with fewer side effects

Status: 1st clinical trial in progress

CBT 127

Indications:Breast Cancer

Product: Monoclonal Antibody

Status: Currently under development

CBT 128

Indications:Wet Age-Related Macular Degeneration

Product: Monoclonal Antibody

Status:Currently under pre-clinical study

Other MAbs

Indications: Oncology

Status: Currently under review for development